| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -5,344,487 | -3,638,193 |
| Depreciation and amortization | 166,093 | 107,729 |
| Share-based compensation | 101,003 | 84,257 |
| Amendment of warrants | 48,087 | 48,087 |
| Non-cash settlements | 58,272 | 58,272 |
| Loss on exchange of debt | 0 | 0 |
| Loss on extinguishment of debt | 0 | 0 |
| Amortization of deferred issuance costs | 0 | 0 |
| Change in fair value related to warrants and derivative | -11,767 | -11,766 |
| Non-cash interest related to bridge funding | 0 | - |
| Accounts receivable | 13,692 | 2,595 |
| Prepaids and other current assets | 164,100 | 232,111 |
| Accounts payable | -214,007 | -268,237 |
| Accrued and other liabilities | -162,168 | -521,837 |
| Note payable, net of discount | 0 | 0 |
| Net cash used in operating activities | -5,536,766 | -4,376,394 |
| Intangible assets patents | 154,639 | 121,810 |
| Fixed assets | 7,802 | 481 |
| Net cash used in investing activities | -162,441 | -122,290 |
| Public offering of common stock and warrants | 14,554,545 | 14,554,545 |
| Registered direct offerings | 5,167,927 | 5,167,927 |
| Common stock cash issuance costs | 2,243,441 | 1,959,643 |
| Exercise of series c warrants | 336,441 | 336,441 |
| Redemption of series b preferred stock | 1,213,590 | 1,213,590 |
| Issuance of common stock and warrants related to public offering, net deductions | 0 | - |
| Proceeds from common stock and warrant rega+ offering | 0 | - |
| Proceeds from sales of c-series preferred stock and warrants | 0 | - |
| Proceeds from equity line | 0 | 0 |
| Repayment of promissory notes | 0 | 0 |
| Bridge fund cash issuance costs | 0 | 0 |
| Preferred stock cash issuance costs | 0 | - |
| Net cash provided by financing activities | 16,601,882 | 16,885,680 |
| Net increase in cash and cash equivalents | 10,902,675 | 12,386,996 |
| Cash and cash equivalents at beginning of period | 463,661 | - |
| Cash and cash equivalents at end of period | 11,366,336 | - |
Aclarion, Inc. (ACONW)
Aclarion, Inc. (ACONW)